drugset / Trial / NCT01397838

Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women

NCT01397838 ↗

Phase 1 Unknown 20 enrolled OsteoBuild Ltd.
NaSingle-groupOpen-labelPrevention

Summary

Recent studies have shown that inhibition of Aquaporine-9 channels may ameliorate the bone degradation process. Pro-bone is an AQ - 9 channels inhibitor. This study is design to evaluate the safety of Pro-bone.

Timeline

Start
2011-09
Primary completion
2011-12
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pro-Bone Unknown 500 mg Oral

Indications